Regulatory Insights

  1. Continuity And Risk Mitigation Following Unexpected QPPV Resignation 5/26/2026

    Rapid escalation and clear interim governance ensured compliance and operational continuity following an unexpected QPPV resignation, reducing inspection risk during a critical pharmacovigilance transition.

  2. Rethinking Patient Representation In Breast Cancer Trials For Better Outcomes 5/22/2026

    Broad patient representation in breast cancer trials is critical, and inclusive trial design improves data relevance, accelerates enrollment, and supports global approval and access.

  3. How Adaptive Design Accelerates Early‑Phase NSCLC Development 5/22/2026

    Adaptive trial designs and an adaptive mindset enable non-small cell lung cancer (NSCLC) sponsors to optimize dose, respond to evolving expectations, and accelerate early‑phase development.

  4. Rare Disease Development: Navigating Small Populations And Complex Protocols 5/22/2026

    Learn how you can navigate the complexity of rare disease development with flexible trial design, integrated regulatory strategy, and data-driven execution built for small populations and global programs.

  5. The Compound Effect Of Specialized Knowledge 5/22/2026

    How does specialized knowledge compound over time into foresight, stronger execution, and more confident decision-making across the drug development lifecycle?

  6. Measuring What Can't Be Seen: How PTSD Clinical Trials Prove A Drug Works 5/22/2026

    PTSD trials expose one of the hardest problems in modern drug development, a reliance on clinician-administered and patient-reported scales to determine whether a therapy truly works.

  7. The Regulatory Governance Gap In Clinical Trial AI 5/21/2026

    Regulators are no longer questioning whether AI belongs in clinical trials; however, they’re demanding a governed infrastructure that makes every AI-driven decision auditable and defensible.

  8. Real-Time Review Is The Most Underrated FDA Story Of The Year 5/21/2026

    The FDA’s real-time review pilot signals a massive shift in clinical operations, where continuously regulator-ready data becomes the foundation of future trial execution.

  9. De-Risk Trials For Accelerated Approval And Pipeline Optimization 5/20/2026

    This e-book explores how AI-powered Historical Clinical Trial Data (HCTD) is reshaping modern trial design for oncology and rare disease research.

  10. Timing And Data Are Critical To Winning BTD For Rare Disease Drugs 5/20/2026

    Breakthrough Therapy designation (BTD) can accelerate rare disease drug development—but timing and evidence are everything. Learn how to position your program for FDA success.